Business Context and Reporting Period
This Form 8-K Current Report was filed by ARTELO BIOSCIENCES, INC. on December 2, 2020, regarding events occurring on November 30, 2020. The Company is incorporated in Nevada and its common stock (ARTL) and warrants (ARTLW) trade on The Nasdaq Stock Market, LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and executive compensation rather than financial performance.
Material Changes
The primary material change reported is the appointment of a new director to the Board of Directors:
- Appointment: Gregory R. Reyes was appointed to the Board effective November 30, 2020, with a term expiring at the 2021 annual meeting of stockholders.
- Background: Dr. Reyes brings extensive experience in pharmaceutical and biotech industries, including prior roles as Senior Vice President at Celgene and Biogen Idec, and as Co-Founder of OROX Biosciences, Inc.
Compensation, Risks, and Unusual Items
The filing details the compensatory arrangements for the newly appointed director:
- Equity Grant: Dr. Reyes was granted an option to purchase 120,000 shares of common stock, vesting monthly over a four-year period, subject to continued service.
- Cash Retainer: The Company intends to pay an annual cash retainer in quarterly installments. Expected compensation is $15,000 to $20,000 for the first year and $20,000 to $30,000 for the second year and thereafter, subject to formal Board approval.
- Expenses: The Company will reimburse all reasonable expenses related to his services.
- Risks/Contingencies: The filing states there are no undisclosed arrangements or transactions required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the formal Board approval of the specific cash retainer amount within the stated ranges.
- Confirm the vesting schedule and exercise terms of the 120,000 share option grant under the 2018 Equity Incentive Plan.
- Review the Company's most recent 10-K or 10-Q for actual financial metrics, as this 8-K contains no financial data.